No abstract

Background: Despite the widescale success of proton pump inhibitors to reducing the incidence of peptic ulcer disease, perforated peptic ulcer (PPU) remains a significant cause of severe complications and death.The implementation of open or surgical repair of PPU should be guided by reliable guidelines which are based on current systematic evidence.Objectives: To assess the comparative efficacy and safety of laparoscopic and open repair of PPU.Methods: A systematic review and meta-analysis was conducted based on retrospective, prospective cohort studies, and randomized clinical trials. Duration of surgery and postoperative complications and death were collected from eligible studies, and the outcomes were pooled using mean differences (MD) or relative risks (RRs) for numerical and binary outcomes, respectively. The estimated variance was expressed as 95% confidence intervals (95% CIs).Results: Forty-five studies were included (8456 patients, 56.08% underwent open repair, 6 prospective studies, 7 randomized clinical trials, and 32 retrospective studies). Compared with open repair, laparoscopic surgeries were associated with longer operative times (MD = 8.36, 95% CI, 0.49-16.22), shorter hospital stay (MD = −2.74, 95% CI, −3.70 to−1.79), a higher risk of suture leakage (RR = 1.91, 95% CI, 1.04-3.49) and lower risks of mortality (RR = 0.57, 95% CI, 0.47-0.70), septic shock (RR = 0.69, 95% CI, 0.49-0.98), renal failure (RR = 0.38, 95% CI, 0.18-0.79), and wound infection (RR = 0.26, 95% CI, 0.19-0.37). Conclusion:Laparoscopic repair of PPU showed promising safety outcomes; however, future well-designed randomized studies are warranted to reduce the observed performance bias and possible selection bias in individual studies.

Aim: This study compares the stage at the presentation of patients with colorectal cancer (CRC) before and after introducing COVID-19 restrictions and the mode of presentation.Methods: This is a retrospective cohort study comparing the incidence of CRC, TNM stage and mode of presentation in the pre-COVID and COVID cohorts at a single UK Trust. All patients discussed at the CRC multidisciplinary team (MDT) from March 2017 to March 2021 were included and split into two cohorts; the pre-COVID group from 01/03/2017 to 29/02/2020 and the COVID group from 01/03/2020 to 28/02/2021. Percentages were used for descriptive statistics. Student's t-test was used for the comparison of demographic variables. Chi-squared test was used for the difference analysis for the categorical data, such as TNM and mode of presentation. P value ≤0.05 was significant.Results: In total, 1373 patients were diagnosed with CRC during the period from March 2017 to March 2021. The pre-COVID group (2017-2020) included 1104 CRC patients, compared to 269 patients in the COVID one (2020-2021). The mean age was higher in the pre-COVID group (p = 0.001). There was a statistically significant increase in the proportion of cases presenting with T4 disease (p = 0.023) and metastatic disease (p = 0.032) in the COVID group compared to the pre-COVID group. There was also a significant increase in the rate of emergency presentations (p < 0.0001). Conclusion:We observed a statistically significant increase in rates of locally advanced (T4) and metastatic (distant) CRC in patients presenting after introducing the COVID-19 lockdown. There was also an increase in emergency presentations. There was no observed difference in nodal status. This may reflect disruption to cancer diagnostic services and the reluctance of patients to access medical care during a pandemic, particularly the elderly.

Globally, colorectal cancer (CRC) is one of the most typical lethal cancers. One of the main factors for better outcomes in CRC management is the early detection of the disease. As an integral component of human metabolism and homeostasis, gut microbiome has recently been a subject of extensive research for its role in the pathogenesis, diagnosis, and treatment of CRC.Microbial dysbiosis (the decrease in beneficial gut flora and the increase of detrimental populations) leads to chronic inflammation and genetic alteration in the host cells, triggering and promoting CRC carcinogenesis. Identifying these microbial changes in depth would potentially isolate the pathogenic microbiota species and establish biomarker models for early detection of CRC. On the other hand, modifying these microbial changes would help formulate preventative and therapeutic strategies for CRC, developing a more precise CRC management plan according to each patient's microbial print. This essay explains gut microbiome composition, microbial changes (dysbiosis) in CRC carcinogenesis, the probability of creating microbiomebased CRC biomarkers, and potential microbiome-targeted treatment options.

Colorectal cancer (CRC) is a common deadly cancer. Early detection and accurate staging of CRC enhance good prognosis and better treatment outcomes. Rectal cancer staging is the cornerstone for selecting the best treatment approach. The standard gold method for rectal cancer staging is pelvic MRI. After staging, combining surgery and chemoradiation is the standard management aiming for a curative outcome.Textural analysis (TA) is a radiomic process that quantifies lesions' heterogenicity by measuring pixel distribution in digital imaging. MRI textural analysis (MRTA) of rectal cancer images is growing in current literature as a future predictor of outcomes of rectal cancer management, such as pathological response to neoadjuvant chemoradiotherapy (NCRT), survival, and tumour recurrence. MRTA techniques could validate alternative approaches in rectal cancer treatment, such as the wait-and-watch (W&W) approach in pathologically complete responders (pCR) following NCRT. We consider this a significant step towards implementing precision management in rectal cancer.In this narrative review, we summarize the current knowledge regarding the potential role of TA in rectal cancer management in predicting the prognosis and clinical outcomes, as well as aim to delineate the challenges which obstruct the implementing of this new modality in clinical practice.